SOURCE: Telzuit Medical Technologies, Inc.

September 24, 2007 08:57 ET

Telzuit Medical Technologies: Technology Update: Patch Cost Reductions

ORLANDO, FL--(Marketwire - September 24, 2007) - Telzuit Medical Technologies, Inc. (OTCBB: TZMT)

--  Telzuit has begun sourcing components from lower-cost suppliers, which
    has resulted in 10% reduction in patch costs
--  Additional savings are in the works than may reduce the price of the
    patch an additional 30-50%
--  The Company is currently utilizing Palm Treo 750s configured for
    Windows Mobile 5.0 until AT&T certifies Windows Mobile 6.0
    

The Company has begun to source components for the patch from lower cost suppliers resulting in an approximate 10% reduction in STATPATCH costs. As volumes increase, we have identified additional supply sources that may reduce costs by an additional 30-50%.

Telzuit is utilizing Palm Treo 750s configured for Windows Mobile 5.0 and will do so until AT&T fully certifies Window Mobile 6.0. We have determined that the Company must move forward in the rollout of the STATPATCH system and will use Windows Mobile 6.0 when available.

About Telzuit Medical Technologies, Inc.

Telzuit Medical Technologies, Inc. is dedicated to providing advanced mobile medicine to patients. The STATPATCH System is a full 12-lead, completely wireless Holter monitor. The STATPATCH System has been approved by the FDA under a 510-K filing. Telzuit also provides ultrasound medical imaging services to physicians in Central Florida through six mobile imaging units. Telzuit is based in Orlando. For more information about Telzuit, its business model and its products, please visit the Company's web site: http://www.telzuit.com

Forward-Looking Statements: Except for factual statements made herein, the information contained in this press release consists of forward-looking statements that involve risks and uncertainties, including the effect of changing economic conditions, competition within the health products industry, customer acceptance of products, and other risks and uncertainties. Such forward-looking statements are not guarantees of performance, and Telzuit results could differ materially from those contained in such statements. These forward-looking statements speak only as of the date of this release, and Telzuit undertakes no obligation to publicly update any forward-looking statements to reflect new information, events or circumstances after the date of this release.

Contact Information

  • Contact:
    Jerry Balter
    Chief Financial Officer
    Telzuit Medical Technologies, Inc.
    407-354-1222